Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
Previously, replicating adenovirus type 5 host range (Ad5hr)-HIV/SIV recombinant priming in combination with SIV envelope boosting, resulted in significant, durable protection in 39% of rhesus macaques after SIVmac251 challenge. Both Env-specific antibody mediating ADCC, and cellular immunity correlated with protection. Here we evaluate the relative immunogenicities of novel HIV proteins and their contribution to protection in a SHIV89.6P model. All groups were primed with Ad-HIVenv89.6P, SIVgag239, and SIVnef239 recombinants. One group was not boosted, one received HIV89.6Pgp140DeltaCFI protein, and one a novel HIV-1 poly-peptide "peptomer". The HIV89.6Pgp140DeltaCFI protein in adjuvant strongly boosted Env-specific antibody and memory T cell responses in blood and tissue, resulting in significant reductions in acute and set point viremia. Macaques not boosted, showed a significant reduction in set point viremia, a full 32 weeks after the last Ad priming immunization. The HIV peptomer-boosted group showed a trend toward chronic viremia reduction, but was not protected.
Patterson
L Jean
LJ
Vaccine Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Beal
Jennifer
J
Demberg
Thorsten
T
Florese
Ruth H
RH
Malkevich
Nina
N
Venzon
David
D
Aldrich
Kris
K
Richardson
Ersell
E
Kalyanaraman
V S
VS
Kalisz
Irene
I
Lee
Eun Mi
EM
Montefiori
David C
DC
Robey
Frank A
FA
Robert-Guroff
Marjorie
M
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D000256:Adenoviridae / Q000235:genetics / Q000502:physiology*; D000818:Animals; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D008253:Macaca mulatta; D008297:Male; D011995:Recombination, Genetic; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity / Q000528:radiation effects; D013601:T-Lymphocytes / Q000276:immunology; D014766:Viremia / Q000517:prevention & control*; D014779:Virus Replication; D054299:env Gene Products, Human Immunodeficiency Virus / Q000008:administration & dosage / Q000276:immunology*
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015395:Histocompatibility Antigens Class I; C110764:Mamu-A 01 antigen; D018449:SAIDS Vaccines; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1